Tyme Technologies, Inc., a biotechnology company developing cancer metabolism-based therapies, completed its acquisition by merger with Syros Pharmaceuticals, Inc., a leader in the development of medicines that control the expression of genes. A cross-office, cross-practice team of Faegre Drinker attorneys supported Tyme in the transaction, which closed on September 16, 2022.
Read the full press release for more information on the deal.
